Aditxt, Inc.
$0.20 -0.0245 +2.03% 9.4M
Company Overview
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
Value Proposition
Aditxt is focused on bringing some of the most needed and promising health innovations and solutions to life in a faster, more efficient way using the power of precision medicine, precision diagnostics and monitoring, precision prevention, and precision treatment, offering an alternative to the one-size-fits-all approach to disease prevention, diagnostics, and treatment. The company's diverse innovation portfolio includes Adimune™, Inc., Adivir™, Inc., and Pearsanta™, Inc., which focus on retraining the immune system, treating infectious diseases, and offering high-quality lab testing, respectively. The diversity of the portfolio not only increases the potential for revenue generation but also reduces risk by not relying solely on one product or service.
Aditxt entered a definitive agreement to acquire EvoFem Biosciences, the creator of Phexxi, the first and only FDA-approved hormone-free contraceptive gel, in December 2023. Evofem posted $13.4 million in net sales of Phexxi in the first nine months of 2023 and is expected to report $18.1 to $18.3 million in net sales for fiscal 2023. The global non-hormonal birth control market was $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031.
Aditxt is also conducting a human clinical trial with Mayo Clinic, studying the central nervous system disorder Stiff-Person Syndrome using their proprietary ADI-100™. Mayo Clinic is currently working to enroll 15 to 20 patients, and initial screenings have begun, with dosing expected to begin in the near term.
Aditxt is executing a strategy designed to reach key clinical or commercial stages for its current programs and expand its portfolio to address additional markets, such as oncology and neurology, aligning with its goal for growth and diversification. The company completed a financing round in September 2023 that raised $10 million in gross proceeds, providing ample runway for the company to meet near-term milestones.
Multi-Billion-Dollar Market Opportunity
Investor Presentation
Investment Highlights
-
Diverse product/service portfolio designed to bring promising health innovations and solutions to life faster and more efficiently
- Aditxt combines expertise and resources spanning operations, finance, M&A, global partnerships, content and marketing, access to labs and research facilities, and more
-
Adimune, Inc. focused on modulating the immune system to address autoimmunity, organ rejection, and allergies
- Technology protected by 7 patent families with 8 US patents granted and 4 pending and 86 foreign patents granted and 14 pending
- Recent notable licensing transactions in similar pre-Phase 3 assets generated upfront payments of $10M to $125M with total deal values exceeding $760M for each asset (source: Cortellis Health Intelligence)
-
Definitive agreement to acquire Evofem Biosciences, creator of Phexxi®
- Evofem achieved preliminary net sales of $18.1 to $18.3 million in 2023, up from $16.8 million in 2022
-
Proprietary AditxtScore platform profiles immune system & monitors reactions to viruses, bacteria, allergens & transplanted organs
- High-capacity CLIA-certified facility in Richmond capable of scaling to process 10M AditxtScore’s annually
-
Building lab testing “anytime/anywhere” model through Pearsanta
- Paradigm shift enabling consumers to access healthcare on demand
- Market roll-out for at-home testing expected to begin in Q2 2024
- Acquired proprietary Mitomic™ early disease and cancer detection platform in January 2024; platform targets liquid biopsy market which is expected to surpass $34.7 billion by 2030
- Acquired proprietary EEG brain monitoring technologies (NeuroCap and NeuroEEG) for telehealth applications in January 2024; addresses market opportunity valued at $1 billion in 2022 and expanding at 10.2% CAGR through 2030
- Led by accomplished team with scientific and commercial experience spanning biotech startups, clinical trial design, and biopharma product development and marketing, and public company management
Sign Up For ADTX Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Aditxt (ADTX) is a client of RedChip Companies, Inc. ADTX agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning upon closing of a financing , and $100,000 of Rule 144 stock (post-split) for 12 months of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.